AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytochrome P450 4F12

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9HCS2

UPID:

CP4FC_HUMAN

Alternative names:

CYPIVF12

Alternative UPACC:

Q9HCS2; E7ET51; O60389; Q5JPJ7; Q9HCS1

Background:

Cytochrome P450 4F12 (CYPIVF12) is a pivotal enzyme in the metabolism of polyunsaturated fatty acids (PUFAs) and xenobiotics. It catalyzes the hydroxylation of carbon hydrogen bonds, with a preference for the omega-2 position, and is involved in the metabolism of the antihistamine drug ebastine. This enzyme plays a crucial role in converting arachidonate to 18-hydroxy arachidonate and in the epoxidation of PUFAs such as docosapentaenoic and docosahexaenoic acids.

Therapeutic significance:

Understanding the role of Cytochrome P450 4F12 could open doors to potential therapeutic strategies, particularly in the modulation of PUFA metabolism and the detoxification of xenobiotics.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.